文献速递银屑病与炎症性皮肤病

Deucravacitinib治疗头皮银屑病:两项III期随机试验的子集分析

Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis.
PubMed 文献 · J Am Acad Dermatol · 2023-12-18

本文为POETYK PSO-1和PSO-2两项全球III期52周双盲试验的汇总二次分析,纳入1084例中重度头皮银屑病患者,随机接受安慰剂、Deucravacitinib 6mg每日一次或阿普米司特30mg每日两次。第16周时,Deucravacitinib在头皮特异性PGA 0/1、PSSI较基线改善≥90%及PSSI变化方面均显著优于安慰剂和阿普米司特,且持续至52周,安全性一致。

要点

  • Deucravacitinib 6mg每日一次显著改善中重度头皮银屑病。
  • 第16周疗效优于安慰剂和阿普米司特,并维持至52周。
  • 安全性特征与整体研究人群一致。

核心结论

  • Deucravacitinib在中重度头皮银屑病改善方面显著优于安慰剂或阿普米司特,且耐受性良好。
  • 连续Deucravacitinib治疗的应答维持至52周。
  • 安全性特征与整个研究人群一致。

研究设计与样本

  • POETYK PSO-1和PSO-2为全球III期、52周、双盲试验,纳入成人中重度银屑病患者。
  • 患者按1:2:1随机接受口服安慰剂、Deucravacitinib 6mg每日一次或阿普米司特30mg每日两次。
  • 本汇总二次分析纳入1084例基线中重度头皮银屑病患者,评估头皮特异性PGA 0/1、PSSI较基线改善≥90%及PSSI变化,不良事件评估至第16周。

主要发现

  • 第16周,Deucravacitinib组头皮特异性PGA 0/1应答率为64.0%,安慰剂组17.3%,阿普米司特组37.7%(P < .0001)。
  • 第16周,Deucravacitinib组PSSI较基线改善≥90%的比例为50.6%,安慰剂组10.5%,阿普米司特组26.1%(P < .0001)。
  • 第16周,Deucravacitinib组PSSI较基线变化优于安慰剂和阿普米司特。
  • 连续Deucravacitinib治疗的应答维持至52周。

关键数值与推荐

  • 头皮特异性PGA 0/1:第16周Deucravacitinib 64.0% vs 安慰剂17.3% vs 阿普米司特37.7%(P < .0001)。
  • PSSI较基线改善≥90%:第16周Deucravacitinib 50.6% vs 安慰剂10.5% vs 阿普米司特26.1%(P < .0001)。
  • PSSI较基线变化:Deucravacitinib优于安慰剂和阿普米司特。

临床怎么用

  • Deucravacitinib 6mg每日一次可作为中重度头皮银屑病的有效治疗选择。
  • 疗效显著优于阿普米司特,支持其在此类患者中的应用。
  • 长期治疗可持续维持头皮应答。

局限性

  • 缺乏轻度头皮银屑病的数据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Scalp involvement in plaque psoriasis is challenging to treat. OBJECTIVE: To evaluate the efficacy and safety of deucravacitinib (DEUC) in scalp psoriasis. METHODS: POETYK PSO-1 and PSO-2 were global phase 3, 52-week, double-blinded trials in adults with moderate to severe psoriasis. Patients were randomized 1:2:1 to oral placebo, DEUC 6 mg once daily, or apremilast 30 mg twice daily. This pooled secondary analysis evaluated scalp-specific Physician Global Assessment score of 0 or 1 (0/1), ≥90% improvement from baseline in Psoriasis Scalp Severity Index, and change from baseline in Psoriasis Scalp Severity Index. Adverse events were evaluated through week 16. RESULTS: Overall, 1084 patients with moderate to severe scalp psoriasis at baseline were included. At week 16, response rates were greater with DEUC versus placebo or apremilast for scalp-specific Physician Global Assessment 0/1 (64.0% vs 17.3% vs 37.7%; P < .0001), ≥90% improvement from baseline in Psoriasis Scalp Severity Index (50.6% vs 10.5% vs 26.1%; P < .0001), and change from baseline in Psoriasis Scalp Severity Index. Responses were maintained through 52 weeks with continuous DEUC. Safety was consistent with the entire study population. LIMITATIONS: Lack of data in milder scalp psoriasis. CONCLUSION: DEUC was significantly more efficacious than placebo or apremilast in improving moderate to severe scalp psoriasis and was well tolerated.

来源:J Am Acad Dermatol,查看原文。版权归原作者所有。

引用

  1. Blauvelt A, Rich P, Sofen H, et al. Deucravacitinib, a selective, allosteric tyrosine kinase 2 inhibitor, in scalp psoriasis: A subset analysis of two phase 3 randomized trials in plaque psoriasis. J Am Acad Dermatol. 2023. PMID: 38122848. doi:10.1016/j.jaad.2023.11.060

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。